Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05794217 · ClinicalTrials.gov registry record
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
A clinical trial of Rare Diseases, sponsored by Sanguine Biosciences.
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 1
- Study location
NCT05794217 is a study of Rare Diseases that is actively recruiting participants, run by Sanguine Biosciences. The registered enrollment target is 20,000 participants, above the 14,618-participant average among 7 other Rare Diseases trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05794217, a study of Rare Diseases, is actively recruiting participants, sponsored by Sanguine Biosciences.
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To collect, preserve, and distribute annotated leukopak biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions. This protocol will be utilized to collect research grade products that are not meant for transfusion.
Conditions Studied
Interventions
- BEHAVIORAL This is a non-interventional study
Study Locations (1)
Massachusetts
- Sanguine Biosciences - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05794217
The ClinicalTrials.gov registry entry for NCT05794217 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 14,618-participant average among 7 other Rare Diseases trials with a reported enrollment target (37% higher). The listed sponsor is Sanguine Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rare Diseases appearing as the primary indexed condition, and to 1 intervention - of which This is a non-interventional study is the first listed.
NCT05794217 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05794217 about?
NCT05794217 is a clinical study titled "A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives". To collect, preserve, and distribute annotated leukopak biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions. This protocol wi...
What is the current status of trial NCT05794217?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2022-09-28. Estimated completion is 2026-12-31.
What conditions does trial NCT05794217 study?
This clinical trial studies the following conditions: Rare Diseases.
What interventions are being tested in trial NCT05794217?
The interventions under investigation include: This is a non-interventional study (BEHAVIORAL).
Who is sponsoring clinical trial NCT05794217?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05794217 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rare Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
RECRUITING · Phase 2
-
Longitudinal Studies of Patient With FPDMM
RECRUITING
-
Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas
RECRUITING · NA
-
Baker Gordon Syndrome Natural History Study
RECRUITING
-
UW Undiagnosed Genetic Diseases Program
RECRUITING
-
Epilepsy Learning Healthcare System (ELHS)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.